drugset / Trial / NCT03202095

Creatine for Treatment of Depression Associated With Type 2 Diabetes

NCT03202095

Phase 4 Withdrawn University of Utah
NaSingle-groupOpen-labelTreatment

Summary

The investigators hypothesize that the administration of a widely available, naturally occurring dietary supplement, creatine monohydrate, will reduce the severity of depression in individuals with type 2 diabetes. The purpose of this study is to determine whether 12 weeks of creatine supplementation is an effective treatment for depression in individuals with type 2 diabetes.

Timeline

Start
2017-08-01
Primary completion
2024-06-10
Completion
2024-06-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Creatine Other / unclassified 5 g Oral